Report Overview

The US Hodgkin Lymphoma drugs market size stood at around USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period

Hodgkins lymphoma is also called Hodgkin disease (HD), mainly occurs due to the infection by Epstein-Barr virus (EBV). HD is a cancer of the lymphatic system in which cancer initiates from a specific type of white blood cells called lymphocytes. It exists in Mo forms, first and most common is classical Hodgkin lymphoma and nodular lymphocyte-predominant Hodgkin lymphoma. In people with HD, lymphocytes grow abnormally and spread beyond the lymphatic system. As the disease progresses, it makes it more difficult for the body to fight infections. However, advances in diagnosis and treatment of HD have helped give people a chance for a full recovery in most cases.

The American Cancer Societys estimates for Hodgkin lymphoma in the United States for 2021 are: about 8,830 new cases (4,830 in males and 4,000 in females) and about 960 deaths (570 males and 390 females). The 5 year relative survival rate for all the patients diagnosed with Hodgkin Lymphoma is about 87% in US



 

Market Growth Drivers

Due to increase in prevalence of Hodgkin lymphoma in pediatric as well as in adults, the market will grow during the forecast period. On the basis of prevalence rate of Hodgkin lymphoma, in 2017, there were an estimated 215,531 people living with Hodgkin lymphoma in the United States. The accelerating demand of treatment and novel therapies also tends to drive the market growth. Effective treatment is either unavailable or unaffordable and introduction of generic version of branded drugs is expected to restrain the growth of the market

Major types of Hodgkin Lymphoma

The most major types of Hodgkin Lymphoma are Classic Hodgkin Lymphoma and Nodular Lymphoma Predominant Hodgkin Lymphoma.